Dima Delia, Oprita Liana, Rosu Ana-Maria, Trifa Adrian, Selicean Cristina, Moisoiu Vlad, Frinc Ioana, Zdrenghea Mihnea, Tomuleasa Ciprian
Department of Hematology, Ion Chiricuta Oncology Institute.
Department of Dentistry.
Onco Targets Ther. 2017 Oct 19;10:5047-5051. doi: 10.2147/OTT.S146973. eCollection 2017.
Acute megakaryocytic leukemia (M7-AML) is a rare form of acute myeloid leukemia (AML), which is associated with poor prognosis. The case presented in the current report is a statement for the difficult diagnosis and clinical management of M7-AML in the context of a previous hematologic disorder of undetermined significance and associated genetic abnormalities. Probably, following the complete hematologic remission and further with induction chemotherapy plus tyrosine kinase inhibitor therapy, the clinical management of this case will be followed by a allogeneic bone marrow transplantation, the only proven therapy to improve overall survival.
急性巨核细胞白血病(M7-AML)是急性髓系白血病(AML)的一种罕见形式,其预后较差。本报告中呈现的病例说明了在既往意义未明的血液系统疾病及相关基因异常背景下,M7-AML诊断困难及临床管理的情况。可能在完全血液学缓解后,进一步进行诱导化疗加酪氨酸激酶抑制剂治疗,该病例的临床管理随后将进行异基因骨髓移植,这是唯一被证实可提高总生存率的治疗方法。